Federal Register of Legislation - Australian Government

Primary content

PB 71 of 2012 Other as amended, taking into account amendments up to National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2018 (No. 1) (PB 1 of 2018)
This instrument revokes and replaces the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (No. PB 108 of 2010) to determine the pharmaceutical benefits that are on the Pharmaceutical Benefits Scheme (PBS) through declarations of drugs and medicinal preparations, and determinations of forms, manners of administration and brands, and provides for related matters (responsible persons, prescribing circumstances, maximum quantities, numbers of repeats, and whether the pharmaceutical benefit is to be available only under special arrangements).
Administered by: Health
Registered 01 Feb 2018
Start Date 01 Feb 2018
End Date 20 Feb 2018
Table of contents.

Commonwealth Coat of Arms of Australia

National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the

National Health Act 1953

Compilation No. 63

Compilation date:                              1 February 2018

Includes amendments up to:            PB 1 of 2018

Registered:                                         1 February 2018

This compilation is in 6 volumes

Volume 1:       sections 1–26 and Schedule 1 (A–C)

Volume 2:       Schedule 1 (D–K)

Volume 3:       Schedule 1 (L–P)

Volume 4:       Schedules 1 (Q–Z), 2 and 3

Volume 5:       Schedule 4 (A–R)

Volume 6:       Schedules 4 (S–Z), 5 and Endnotes

Each volume has its own contents

 

About this compilation

This compilation

This is a compilation of the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012) that shows the text of the law as amended and in force on 1 February 2018 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self‑repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

  


Contents

1............................ Name of Instrument...................................................................................... 1

4............................ Definitions.................................................................................................... 1

5............................ Drugs and medicinal preparations to which Part VII applies........................ 2

6............................ Form............................................................................................................. 3

7............................ Manner of administration.............................................................................. 3

8............................ Brand and responsible person....................................................................... 3

8A......................... Schedule equivalent....................................................................................... 4

9............................ Authorised prescriber.................................................................................... 4

10.......................... Prescription circumstances—Schedule 1....................................................... 5

11.......................... Authority required procedures...................................................................... 5

12.......................... Authority required procedures—submission of prescription........................ 6

13.......................... Authority required procedures—authorisation.............................................. 7

14.......................... Streamlined authority code............................................................................ 8

15.......................... Extended application of sections 11 to 14..................................................... 8

16.......................... Prescription circumstances—Schedule 2....................................................... 8

17.......................... Maximum quantity—Schedule 1................................................................... 9

18.......................... Maximum quantity conditions—Schedule 1............................................... 10

19.......................... Maximum quantity—Schedule 2................................................................. 10

20.......................... Maximum number of repeats—Schedule 1................................................. 10

21.......................... Maximum number of repeats conditions—Schedule 1................................ 11

22.......................... Maximum number of repeats—Schedule 2................................................. 11

23.......................... Determined Quantity................................................................................... 11

24.......................... Pack Quantity.............................................................................................. 12

25.......................... Section 100 only supply.............................................................................. 12

26.......................... Prescriber bag only supply.......................................................................... 13

Schedule 1—Ready‑prepared pharmaceutical benefits                                 15


  

  

1  Name of Instrument

             (1)  This Instrument is the National Health (Listing of Pharmaceutical Benefits) Instrument 2012.

             (2)  This Instrument may also be cited as PB 71 of 2012.

4  Definitions

                   In this Instrument:

ABN has the same meaning as in the A New Tax System (Australian Business Number) Act 1999;

Act means the National Health Act 1953;

authorised prescriber for a pharmaceutical benefit, means a kind of person identified by a prescriber code mentioned in the column in Schedule 1 headed ‘Authorised Prescriber’ for the benefit;

CFC means chlorofluorocarbon;

CFU means colony forming unit;

circumstances code means the letter ‘C’ followed by a number;

conditions code means the letters ‘CN’ followed by a number;

electronic communication has the meaning given by subsection 5(1) of the Electronic Transactions Act 1999;

electronic prescription has the meaning given by the Regulations;

extemporaneously‑prepared pharmaceutical benefit means a pharmaceutical benefit other than a ready‑prepared pharmaceutical benefit;

General Statement for drugs for the treatment of hepatitis C means the statement set out in Part 3 of Schedule 4;

General Statement for Lipid‑Lowering Drugs means the statement set out in Part 2 of Schedule 4;

GP Management Plan means a comprehensive written plan for the treatment of a patient, prepared by a medical practitioner, that includes a description of the patient’s health care needs, management goals, actions to be taken by the patient and treatment and services the patient is likely to need;

I.M. means intramuscular;

I.U. means international unit;

I.V. means intravenous;

Medicare Benefits Schedule means the Health Insurance (General Medical Services Table) Regulations;

mmol means millimole;

palliative care patient means a patient with an active, progressive, far‑advanced disease for whom the prognosis is limited and the focus of care is the quality of life;

paper-based prescription has the meaning given by the Regulations;

PBS means Pharmaceutical Benefits Scheme;

prescriber code means any of the following codes identifying the kind of person mentioned for the code:

                     (a)  MP—medical practitioner;

                     (b)  PDP—participating dental practitioner;

                     (c)  AO—authorised optometrist;

                     (d)  MW—authorised midwife;

                     (e)  NP—authorised nurse practitioner;

purposes code means the letter ‘P’ followed by a number;

ready‑prepared pharmaceutical benefit means a brand of a pharmaceutical item in relation to which a determination under subsection 85(6) of the Act is in force;

Regulations means the National Health (Pharmaceutical Benefits) Regulations 1960;

residential care service has the meaning given by the Regulations;

Streamlined Authority Code means the words ‘Streamlined Authority Code’ followed by a number;

Team Care Arrangements means a document prepared by a medical practitioner, following consultation with collaborating providers, that includes a description of the treatment and service goals for the patient, the treatment and services that all collaborating providers will provide and the actions to be taken by the patient;

TGA means Therapeutic Goods Administration;

WHO means World Health Organisation.

Note:          Terms used in this Instrument have the same meaning as in the Act—see section 13 of the Legislative Instruments Act 2003. These terms include:

·      Chief Executive Medicare

·      pharmaceutical benefit

·      pharmaceutical item.

5  Drugs and medicinal preparations to which Part VII applies

             (1)  For paragraph 85(2)(a) of the Act, Part VII of the Act applies to:

                     (a)  a drug or medicinal preparation mentioned in the column headed ‘Listed Drug’ in:

                              (i)  Schedule 1; or

                             (ii)  Part 1 of Schedule 2; and

                     (b)  a medicinal preparation composed of 1 or more listed drugs mentioned in subparagraph (a)(ii).

             (2)  For subparagraph 85(2)(b)(i) of the Act, paragraph 85(2)(b) of the Act applies to a listed drug mentioned in subparagraph (1)(a)(ii).

             (3)  For subparagraph 85(2)(b)(ii) of the Act, paragraph 85(2)(b) of the Act applies to an additive mentioned in Part 2 of Schedule 2.

Note:          Part VII of the Act applies to medicinal preparations composed of 1 or more listed drugs mentioned in subsection (2) and 1 or more of the additives mentioned in subsection (3)—see paragraph 85(2)(b) of the Act.

6  Form

                   For subsection 85(3) of the Act, the column headed ‘Form’ in Schedule 1 lists the form or forms for a listed drug determined for that drug.

7  Manner of administration

             (1)  For subsection 85(5) of the Act, the manner of administration of a form of a listed drug mentioned in Schedule 1 is the manner of administration mentioned for that form of the drug in the column headed ‘Manner of Administration’ in Schedule 1.

             (2)  For paragraph 85A(2)(c) of the Act, if a manner of administration is mentioned in Schedule 1 for a form of a listed drug, a person writing a prescription for the supply of a pharmaceutical benefit that has the listed drug in that form must, if including a manner of administration in the prescription, direct that the pharmaceutical benefit be administered in that manner.

             (3)  For subsection (2), the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

8  Brand and responsible person

             (1)  A brand mentioned in the column headed ‘Brand’ in Schedule 1 for a pharmaceutical item is determined for subsection 85(6) of the Act for that pharmaceutical item.

             (2)  For subsection 84AF(1) of the Act, if a code is mentioned in the column in Schedule 1 headed ‘Responsible Person’ for a brand of a pharmaceutical item, the person mentioned in subsection (3) is the responsible person for the brand of the pharmaceutical item.

             (3)  For subsection (2), the person is the person mentioned in Schedule 3 for the code, with the ABN, if any, mentioned in Schedule 3 for the person.

             (4)  For subsections (1) and (2), the pharmaceutical item is the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

8A  Schedule equivalent

             (1)  For subsection 85(6A) of the Act:

                     (a)  a brand of a pharmaceutical item with an ‘a’ located in the column headed ‘Schedule Equivalent’ in Schedule 1, is to be treated as equivalent to another brand of that pharmaceutical item that also has an ‘a’ located in the column headed ‘Schedule Equivalent’ in Schedule 1;

                     (b)  where paragraph (a) applies to a brand of a pharmaceutical item, a brand of the same pharmaceutical item with a ‘b’ in the column headed ‘Schedule equivalent’ in Schedule 1, is to be treated as equivalent to another brand of that pharmaceutical item that also has a ‘b’ located in the column headed ‘Schedule Equivalent’ in Schedule 1; and

                     (c)  where a brand of a pharmaceutical item appears in Schedule 5, that brand is to be treated as equivalent to any brand of any pharmaceutical item that is in the same schedule equivalent group as that brand in Schedule 5.

9  Authorised prescriber

             (1)  For subsection 88(1A) of the Act, a participating dental practitioner is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials PDP are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.

             (2)  For subsection 88(1C) of the Act, an authorised optometrist is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials AO are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.

             (3)  For subsection 88(1D) of the Act, an authorised midwife is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials MW are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.

             (4)  For subsection 88(1E) of the Act, an authorised nurse practitioner is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials NP are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.

             (5)  For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Note:          A medical practitioner may prescribe any pharmaceutical benefit—see subsection 88(1) of the Act.

10  Prescription circumstances—Schedule 1

             (1)  This section applies to a pharmaceutical benefit if at least 1 circumstances code is mentioned in the column in Schedule 1 headed ‘Circumstances’ for the pharmaceutical benefit.

             (2)  For paragraph 85(7)(a) of the Act, the pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A of the Act.

             (3)  For paragraph 85(7)(b) of the Act, the circumstances in which a prescription for the supply of the pharmaceutical benefit may be written are the circumstances mentioned in Part 1 of Schedule 4 for at least 1 of the circumstances codes mentioned in Schedule 1 for the pharmaceutical benefit.

             (4)  For subsection (1), the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

11  Authority required procedures

             (1)  This section applies to a pharmaceutical benefit if the circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit include any of the following:

                     (a)  Compliance with Authority Required procedures;

                     (b)  Compliance with Written Authority Required procedures;

                     (c)  Compliance with Telephone Authority Required procedures;

                     (d)  Compliance with Written or Telephone Authority Required procedures.

          (1A)  If the circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit include the words ‘Compliance with Telephone Authority Required procedures’ or ‘Compliance with Written or Telephone Authority Required procedures’ treat as if the words used are ‘Compliance with Authority Required procedures’.

Note:          If there is a Streamlined Authority Code section 14 continues to apply.

             (2)  A prescription for the supply of the pharmaceutical benefit must be:

                     (a)  submitted by the authorised prescriber to the Chief Executive Medicare in accordance with section 12; and

                     (b)  authorised by the Chief Executive Medicare in accordance with section 13.

             (3)  In all circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit, except those which include a Streamlined Authority Code, a medication chart prescription for a person receiving treatment in a residential care service may not be authorised under the authority required procedures in sections 11 to 15.

12  Authority required procedures—submission of prescription

             (1)  A prescription is submitted in accordance with this subsection if:

                     (a)  the authorised prescriber submits to the Chief Executive Medicare:

                              (i)  the prescription itself; or

                             (ii)  for a medication chart prescription that is not an electronic prescription — the medication chart by which the prescription was written, or a copy of so much of that chart as would indicate that subregulation 19AA(2) of the Regulations has been complied with; or

                     (b)  the authorised prescriber submits details of the prescription by telephone to the Chief Executive Medicare; or

                     (c)  the authorised prescriber submits the prescription in accordance with the instructions in an emergency telephone message provided to the authorised prescriber by the Chief Executive Medicare; or

                     (d)  the authorised prescriber submits details of the prescription in accordance with subsection 12(4A) to the Chief Executive Medicare, by means of electronic communication to obtain an electronic authority.

             (2)  If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Written Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(a).

             (3)  If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Telephone Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(b) or (c).

             (4)  If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Written or Telephone Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(a), (b) or (c).

          (4A)  The prescription submitted in accordance with paragraph 12(1)(d) must be:

                     (a)  given to the Chief Executive Medicare in writing; and

                     (b)  by means of an electronic communication; and

                     (c)  encrypted when it is given to the Chief Executive Medicare; and

                     (d)  in accordance with any other requirements that would need to be met in order for the requirements to give the information in writing to be taken to have been met under the Electronic Transactions Act 1999.

             (5)  For paragraph (1)(a), a prescription prepared and signed by the authorised prescriber in accordance with subsection (1) is taken to have been submitted by the authorised prescriber if it is submitted by his or her employee.

13  Authority required procedures—authorisation 

             (1)  A paper-based prescription (other than a prescription submitted in accordance with paragraph 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare signing his or her authorisation on the prescription, and:

                     (a)  if the Chief Executive Medicare requires the authorised prescriber to alter the prescription — returning it to the authorised prescriber for alteration before the authorised prescriber gives it to the person in respect of whom it was prepared; or

                     (b)  by returning it to the authorised prescriber; or

                     (c)  if requested by the authorised prescriber — sending it to the person in respect of whom it was prepared.

          (1A)  A medication chart prescription (other than an electronic prescription, or a prescription submitted in accordance with paragraphs 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare signing his or her authorisation on the medication chart prescription, or a copy of the medication chart prescription, and:

                     (a)  if the Chief Executive Medicare requires the authorised prescriber to alter the prescription— indicating this on the medication chart prescription or copy; and

                     (b)  returning the medication chart or copy to the authorised prescriber for alteration.

          (1B)  An electronic prescription (other than a prescription submitted in accordance with paragraphs 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare writing his or her authorisation on the electronic prescription, and:

                     (a)  if the Chief Executive Medicare requires the authorised prescriber to alter the prescription— by returning it, including by means of an electronic communication, to the authorised prescriber for alteration; or

                     (b)  by returning it, including by means of electronic communication to the authorised prescriber; or

                     (c)  if requested by the authorised prescriber — sending it to the person in respect of whom it was prepared.

             (2)  A prescription submitted in accordance with paragraph 12(1)(b) may be authorised by the Chief Executive Medicare telling the authorised prescriber by telephone, at the time the Chief Executive Medicare is given details of the prescription, that the prescription is authorised.

             (3)  A prescription submitted in accordance with paragraph 12(1)(d) may be authorised by the Chief Executive Medicare sending his or her authorisation, by electronic communication, including computer automated electronic communication, to the authorised prescriber.

          (3A)  If the prescription submitted is declined for authorisation, the authorised prescriber may seek review of the decision by the Chief Executive Medicare.

             (4)  If the Chief Executive Medicare authorises a prescription under subsection (2) or (3):

                     (a)  the Chief Executive Medicare must tell the authorised prescriber the number that has been allotted to the authorised prescription: and

                     (b)  the authorised prescriber must:

                              (i)  mark that number on the prescription; and

                             (ii)  retain a copy of the prescription showing the number marked in accordance with subparagraph (i) for 1 year from the date the prescription was authorised.

             (5)  For paragraph (4)(a), the Chief Executive Medicare must tell the authorised prescriber the number:

                              (i)  if the authorised prescriber is an authorised optometrist—by telephone; and

                             (ii)  in any other case—by telephone or by electronic communication.

             (6)  A prescription submitted in accordance with paragraph 12(1)(c) is taken to have been authorised by the Chief Executive Medicare if the authorised prescriber completes the prescription in accordance with the instructions given in the emergency telephone message.

14  Streamlined authority code

             (1)  This section applies to a pharmaceutical benefit if the circumstances mentioned in Schedule 4 for a circumstances code applying to the pharmaceutical benefit include a Streamlined Authority Code.

             (2)  The requirements of section 12 are taken to have been complied with, and the Chief Executive Medicare is taken to have authorised the prescription of the pharmaceutical benefit under section 13, if the authorised prescriber has written the Streamlined Authority Code on the prescription.

15  Extended application of sections 11 to 14

                 Sections 11 to 14 apply in relation to conditions and conditions codes as if the circumstances and circumstances codes mentioned in those sections were conditions and conditions codes.

Note:             Conditions are determined in sections 18 and 21.

16  Prescription circumstances—Schedule 2

             (1)  For paragraph 85(7)(a) of the Act, a pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A if:

                     (a)  it is:

                              (i)  a listed drug mentioned in Part 1 of Schedule 2; or

                             (ii)  an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug; and

                     (b)  there are circumstances mentioned for the listed drug in the column headed ‘Circumstances’ in Part 1 of Schedule 2.

             (2)  For paragraph 85(7)(b) of the Act, the circumstances in which a prescription for the supply of a pharmaceutical benefit mentioned in subsection (1) may be written are:

                     (a)  for a listed drug mentioned in subparagraph (1)(a)(i)—the circumstances mentioned in the column headed ‘Circumstances’ in Part 1 of Schedule 2 for the drug; and

                     (b)  for an extemporaneously‑prepared pharmaceutical benefit mentioned in subparagraph (1)(a)(ii)—the circumstances mentioned in the column headed ‘Circumstances’ in Part 1 of Schedule 2 for each listed drug contained in the pharmaceutical benefit.

Note:          If an extemporaneously‑prepared pharmaceutical benefit contains more than one listed drug, a prescription for the supply of the pharmaceutical benefit may only be written if the circumstances mentioned for each of the listed drugs contained in the pharmaceutical benefit are met.

17  Maximum quantity—Schedule 1

             (1)  For paragraph 85A(2)(a) of the Act, the maximum quantity or number of units of the pharmaceutical item in a pharmaceutical benefit mentioned in Schedule 1 that may, in 1 prescription for the supply of the pharmaceutical benefit, be directed by an authorised prescriber to be supplied on any 1 occasion is the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for the pharmaceutical benefit and authorised prescriber.

             (2)  If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for a pharmaceutical benefit, the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ is the maximum for the particular purposes mentioned in Schedule 4 for each purposes code.

             (3)  If no purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’, the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.

             (4)  For subsection (1) the pharmaceutical item is the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

             (5)  For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

18  Maximum quantity conditions—Schedule 1

             (1)  This section applies to a pharmaceutical benefit if a conditions code is mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for a maximum quantity or number of units for the pharmaceutical benefit.

             (2)  For subsection 85A(2A) of the Act, the conditions which must be satisfied when writing a prescription for the supply of the pharmaceutical benefit to which a determination of a maximum quantity or number of units under paragraph 85A(2)(a) applies, are the conditions mentioned in Part 1 of Schedule 4 for the conditions code mentioned in Schedule 1 for the pharmaceutical benefit and the maximum quantity or number of units.

             (3)  For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

19  Maximum quantity—Schedule 2

             (1)  For paragraph 85A(2)(a) of the Act, the maximum quantity or number of units of an extemporaneously‑prepared pharmaceutical benefit of a type mentioned in Part 3 of Schedule 2 that may, in 1 prescription for the supply of the pharmaceutical benefit, be directed by an authorised prescriber to be supplied on any 1 occasion is the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ in Part 3 of Schedule 2 for that type of pharmaceutical benefit.

             (2)  For subsection (1), the extemporaneously‑prepared pharmaceutical benefit is:

                     (a)  the listed drug mentioned in Part 1 of Schedule 2; or

                     (b)  an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug.

20  Maximum number of repeats—Schedule 1

             (1)  For paragraph 85A(2)(b) of the Act, the maximum number of occasions an authorised prescriber may, in 1 prescription, direct that the supply of a pharmaceutical benefit mentioned in Schedule 1 be repeated is the number in the column in Schedule 1 headed ‘Number of Repeats’ for the pharmaceutical benefit and the authorised prescriber.

             (2)  If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for the pharmaceutical benefit, the number of repeats mentioned in the column in Schedule 1 headed ‘Number of Repeats’ is the maximum for the particular purposes mentioned in Schedule 4 for each purposes code.

             (3)  If no purposes code is mentioned in the column headed ‘Purposes’, the number of repeats mentioned in the column headed ‘Number of Repeats’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.

             (4)  For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

21  Maximum number of repeats conditions—Schedule 1

             (1)  This section applies to a pharmaceutical benefit if a conditions code is mentioned in the column in Schedule 1 headed ‘Number of Repeats’ for the maximum number of repeats for the pharmaceutical benefit.

             (2)  For subsection 85A(2A) of the Act, the conditions which must be satisfied when writing a prescription for the supply of the pharmaceutical benefit to which a determination of a maximum number of repeats under paragraph 85A(2)(b) applies, are the conditions mentioned in Part 1 of Schedule 4 for the conditions code mentioned in Schedule 1 for the pharmaceutical benefit and the maximum number of repeats.

             (3)  For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

22  Maximum number of repeats—Schedule 2

             (1)  For paragraph 85A(2)(b) of the Act, the maximum number of occasions an authorised prescriber may, in 1 prescription, direct that the supply of an extemporaneously‑prepared pharmaceutical benefit of a type mentioned in Part 3 of Schedule 2 be repeated is the number in the column headed ‘Number of Repeats’ in Part 3 of Schedule 2 for that type of pharmaceutical benefit.

             (2)  For this section, the extemporaneously‑prepared pharmaceutical benefit is:

                     (a)  the listed drug mentioned in Part 1 of Schedule 2; or

                     (b)  an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug.

23  Determined Quantity

             (1)  For subsection 84AK(3) of the Act, the quantities or numbers of units of a pharmaceutical item that are determined quantities of a listed brand of the pharmaceutical item mentioned in Schedule 1 are the quantities or numbers of units mentioned in the column in Schedule 1 headed ‘Determined Quantity’ for the listed brand of the pharmaceutical item.

             (2)  For this section, the listed brand of the pharmaceutical item is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

             (3)  For this section, the pharmaceutical item is the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

24  Pack Quantity

             (1)  For subsection 84AK(2) of the Act, the quantities or numbers of units of a pharmaceutical item that are pack quantities of a listed brand of the pharmaceutical item mentioned in Schedule 1 are the quantities or numbers of units mentioned in the column in Schedule 1 headed ‘Pack Quantity’ for the listed brand of the pharmaceutical item.

             (2)  For this section, the listed brand of the pharmaceutical item is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

             (3)  For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

25  Section 100 only supply

             (1)  For subsection 85(2A) of the Act, if the code D(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a listed drug, the drug can only be supplied under special arrangements under section 100 of the Act.

             (2)  For paragraph 85(8)(a) of the Act, if the code PB(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, the pharmaceutical benefit can only be supplied under special arrangements under section 100 of the Act.

             (3)  For paragraph 85(8)(b) of the Act, if the code C(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, and a circumstances code is mentioned for the pharmaceutical benefit in the column headed ‘Circumstances’, the pharmaceutical benefit can be supplied in the circumstances identified in Part 1 of Schedule 4 for the circumstances code only under special arrangements under section 100 of the Act.

             (4)  For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

26  Prescriber bag only supply

             (1)  For subsection 85(2AA) of the Act, if one or more of the codes D(MP), D(MW) and D(NP) are mentioned in the column headed ‘Section 100/ Prescriber Bag only’ in Schedule 1 for a listed drug other than the drug methoxyflurane, then, subject to subsection (3), the drug can only be supplied by:

                     (a)  where the code D(MP) is mentioned, medical practitioners under section 93 of the Act, and

                     (b)  where the code D(MW) is mentioned, authorised midwives under section 93AA of the Act, and

                     (c)  where the code D(NP) is mentioned, authorised nurse practitioners under section 93AB of the Act.

Note:          A declaration in force immediately before 1 October 2012 for the purposes of subsection 85(2A) of the Act declaring that the drug methoxyflurane can only be supplied under special arrangements under section 100 of the Act, continues in force and may be dealt with on and after 1 October 2012, as if the declaration had been made for the purposes of subsection 85(2AA) of the Act and declared that methoxyflurane can only be supplied under section 93 of the Act (see Item 18 of Schedule 3 to the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2012).

             (2)  For subsection 85(7A) of the Act, if one or more of the codes PB(MP), PB(MW) and PB(NP) are mentioned in the column headed ‘Section 100/ Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, then, subject to subsection (3), the pharmaceutical benefit can only be supplied by:

                     (a)  where the code PB(MP) is mentioned, medical practitioners under section 93 of the Act, and

                     (b)  where the code PB(MW) is mentioned, authorised midwives under section 93AA of the Act, and

                     (c)  where the code PB(NP) is mentioned, authorised nurse practitioners under section 93AB of the Act.

             (3)  If :

                     (a)  one or more of the codes D(MP), D(MW), and D(NP) are mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a listed drug; and

                     (b)  one or more of the codes PB(MP), PB(MW) and PB(NP) are also mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit having the listed drug;

then:

                     (c)  the drug may be supplied as provided in subsection (1): and

                     (d)  the pharmaceutical benefit may be supplied as provided in subsection (2).

             (4)  For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.


Schedule 1Ready‑prepared pharmaceutical benefits

(sections 5 to 10, 16 to 18, 20, 21, 23 to 26)

 

Listed Drug

Form

Manner of Administration

Schedule Equivalent

Brand

Responsible Person

Authorised Prescriber

Circumstances

Purposes

Maximum Quantity

Number of Repeats

Pack Quantity

Determined Quantity

Section 100/ Prescriber Bag only

Abacavir

Tablet 300 mg (as sulfate)

Oral

 

Ziagen

VI

MP

C4454 C4512

 

120

5

60

 

D(100)

Oral solution 20 mg (as sulfate) per mL, 240 mL

Oral

 

Ziagen

VI

MP

C4454 C4512

 

8

5

1

 

D(100)

Abacavir with Lamivudine

Tablet containing abacavir 600 mg (as hydrochloride) with lamivudine 300 mg

Oral

 

Abacavir/Lamivudine GH 600/300

GQ

MP

C4527 C4528

 

60

5

30

 

D(100)

 

Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg

Oral

 

Kivexa

VI

MP

C4527 C4528

 

60

5

30

 

D(100)

Abacavir with Lamivudine and Zidovudine

Tablet containing abacavir 300 mg (as sulfate) with lamivudine 150 mg and zidovudine 300 mg

Oral

 

Trizivir

VI

MP

C4480 C4495

 

120

5

60

 

D(100)

Abatacept

Injection 125 mg in 1 mL single dose autoinjector

Injection

 

Orencia ClickJect

BQ

MP

C6849 C6859 C6866 C6867 C6874

P6849 P6867 P6874

4

3

4

 

 

 

 

 

 

 

 

MP

C6849 C6859 C6866 C6867 C6874

P6859 P6866

4

5

4

 

 

 

Injection 125 mg in 1 mL single dose pre‑filled syringe

Injection

 

Orencia

BQ

MP

C6849 C6859 C6866 C6867 C6874

P6849 P6867 P6874

4

3

4

 

 

MP

C6849 C6859 C6866 C6867 C6874

P6859 P6866

4

5

4

 

Powder for I.V. infusion 250 mg

Injection

 

Orencia

BQ

MP

See Note 3

See Note 3

See Note 3

See
Note 3

1

 

PB(100)

Abciximab

I.V. injection 10 mg in 5 mL vial

Injection

 

ReoPro

JC

MP

C4915 C4942 C4943

3

0

1

 

 

Abiraterone

Tablet containing abiraterone acetate 250 mg

Oral

 

Zytiga

JC

MP

C6944

 

120

2

120

 

 

 

Tablet containing abiraterone acetate 500 mg

Oral

 

Zytiga

JC

MP

C6944

 

60

2

60

 

 

Acamprosate

Tablet (enteric coated) containing acamprosate calcium 333 mg

Oral

 

Campral

AF

MP NP

C5366

 

180

1

180

 

 

Acarbose

Tablet 50 mg

Oral

a

Acarbose Mylan

AF

MP NP

 

 

90

5

90

 

 

 

 

 

a

Glucobay 50

BN

MP NP

 

 

90

5

90

 

 

 

Tablet 100 mg

Oral

a

Acarbose Mylan

AF

MP NP

 

 

90

5

90

 

 

 

 

 

a

Glucobay 100

BN

MP NP

 

 

90

5

90

 

 

Acetazolamide

Tablet 250 mg

Oral

 

Diamox

RW

MP NP

 

 

100

3

100

 

 

Aciclovir

Eye ointment 30 mg per g, 4.5 g

Application to the eye

 

Zovirax

GK

MP NP

C5965

 

1

0

1

 

 

 

 

 

 

 

 

AO

C5964

 

1

0

1

 

 

 

Tablet 200 mg

Oral

a

Aciclovir Sandoz

HX

MP NP

C5936 C5942

P5936

50

0

25

 

 

 

 

 

a

GenRx Aciclovir

GX

MP NP

C5936 C5942

P5936

50

0

50

 

 

 

 

 

a

Aciclovir 200

CR

MP NP

C5942

 

90

5

90

 

 

 

 

 

a

Aciclovir AN

ED

MP NP

C5942

 

90

5

90

 

 

 

 

 

a

Aciclovir GH

GQ

MP NP

C5942

 

90

5

90

 

 

 

 

 

a

Aciclovir Sandoz

HX

MP NP

C5936 C5942

P5942

90

5

90

 

 

 

 

 

a

Acyclo‑V 200

AF

MP NP

C5942

 

90

5

90

 

 

 

 

 

a

GenRx Aciclovir

GX

MP NP

C5936 C5942

P5942

90

5

90

 

 

 

 

 

a

Lovir

EA

MP NP

C5942

 

90

5

90

 

 

 

 

 

a

Ozvir

RA

MP NP

C5942

 

90

5

90

 

 

 

 

 

a

Zovirax 200 mg

GK

MP NP

C5942

 

90

5

90

 

 

 

Tablet 800 mg

Oral

a

Aciclovir 800

CR

MP NP

C5959 C5967

 

35

0

35

 

 

 

 

 

a

Aciclovir Sandoz

HX

MP NP

C5959 C5967

 

35

0

35

 

 

 

 

 

a

GenRx Aciclovir

GX

MP NP

C5959 C5967

 

35

0

35

 

 

Acitretin

Capsule 10 mg

Oral

a

Neotigason

UA

MP

C5727 C5789

 

100

2

100

 

 

 

 

 

a

Novatin

TX

MP

C5727 C5789

 

100

2

100

 

 

 

 

 

a

ZETIN

RW

MP

C5727 C5789

 

100

2

100

 

 

 

Capsule 25 mg

Oral

a

Neotigason

UA

MP

C5727 C5789

 

100

2

100

 

 

 

 

 

a

Novatin

TX

MP

C5727 C5789

 

100

2

100

 

 

 

 

 

a

ZETIN

RW

MP

C5727 C5789

 

100

2

100

 

 

Aclidinium

Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses

Inhalation by mouth

 

Bretaris Genuair

FK

MP NP

C4516

 

1

5

1

 

 

Aclidinium with eformoterol

Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses

Inhalation by mouth

 

Brimica Genuair

FK

MP NP

C5763

 

1

5

1

 

 

Adalimumab

Injection 20 mg in 0.4 mL pre‑filled syringe

Injection

 

Humira

VE

MP

See Note 3

See Note 3

See Note 3

See
Note 3

2

 

C(100)

 

 

 

 

 

 

MP

C5076 C5091 C5105 C5116 C5117 C6916 C6917 C6918 C6921 C6931 C6932

P5105

2

0

2

 

 

 

 

 

 

 

 

MP

C5076 C5091 C5105 C5116 C5117 C6916 C6917 C6918 C6921 C6931 C6932

P5076 P5117 P6918 P6931 P6932

2

3

2

 

 

 

 

 

 

 

 

MP

C5076 C5091 C5105 C5116 C5117 C6916 C6917 C6918 C6921 C6931 C6932

P5091 P5116 P6916 P6917 P6921

2

5

2

 

 

 

Injection 40 mg in 0.8 mL pre‑filled syringe

Injection

 

Humira

VE

MP

See Note 3

See Note 3

See Note 3

See
Note 3

2

 

C(100)

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P5105

2

0

2

 

 

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P3695 P3747 P5074 P5076 P5090 P5117 P6918 P6931 P6932 P7151

2

2

2

 

 

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P4492 P4501 P4518 P4610 P4700 P4851 P6430 P6437 P6445 P6458 P6902 P6923

2

3

2

 

 

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P6695 P6726 P6727 P6728 P6753

2

4

2

 

 

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P3697 P3748  P4517 P4531 P4643 P4724 P4845 P5075 P5091 P5116 P6423 P6439 P6696 P6755 P6756 P6916 P6917 P6921 P6922

2

5

2

 

 

 

Injection 40 mg in 0.8 mL pre‑filled pen

Injection

 

Humira

VE

MP

See Note 3

See Note 3

See Note 3

See
Note 3

2

 

C(100)

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P5105

2

0

2

 

 

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P3695 P3747 P5074 P5076 P5090 P5117 P6918 P6931 P6932 P7151

2

2

2

 

 

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P4492 P4501 P4518 P4610 P4700 P4851 P6430 P6437 P6445 P6458 P6902 P6923

2

3

2

 

 

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610  C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P6695 P6726 P6727 P6728 P6753

2

4

2

 

 

 

 

 

 

 

 

MP

C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5116 C5117 C6423 C6430 C6437 C6439 C6445 C6458 C6695 C6696 C6726 C6727 C6728 C6753 C6755 C6756 C6902 C6916 C6917 C6918 C6921 C6922 C6923 C6931 C6932 C7151

P3697 P3748  P4517 P4531 P4643 P4724 P4845 P5075 P5091 P5116 P6423 P6439 P6696 P6755 P6756 P6916 P6917 P6921 P6922

2

5

2

 

 

 

Injection 40 mg in 0.8 mL pre-filled pen, 4

Injection

 

Humira

VE

MP

C6946 C6971 C6972

P6946

1

2

1

 

 

 

 

 

 

 

 

MP

C6946 C6971 C6972

P6971 P6972

1

5

1

 

 

 

Injection 40 mg in 0.8 mL pre‑filled syringe, 6

Injection

 

Humira

VE

MP

C3695 C3747 C5074 C5076 C5090 C5117 C6918 C6931 C6932 C7151

 

1

0

1

 

 

 

Injection 40 mg in 0.8 mL pre‑filled pen, 6

Injection

 

Humira

VE

MP

C3695 C3747 C5074 C5076 C5090 C5117 C6918 C6931 C6932 C6951 C6963 C7151

 

1

0

1

 

 

Adapalene with benzoyl peroxide

Gel 1 mg‑25 mg per g, 30 g

Application

 

Epiduo

GA

MP

C4898 C4961

P4961

1

1

1

 

 

 

 

 

 

 

 

MP

C4898 C4961

P4898

1

3

1

 

 

 

 

 

 

 

 

NP

C4898

 

1

3

1

 

 

Adefovir

Tablet containing adefovir dipivoxil 10 mg

Oral

 

APO-Adefovir

TX

MP

C4490 C4510

 

60

5

30

 

D(100)

 

 

 

 

Hepsera

GI

MP

C4490 C4510

 

60

5

30

 

D(100)

Adrenaline

Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000)

Injection

 

Link Medical Products Pty Ltd

LM

PDP

 

 

5

0

5

 

 

 

 

 

 

 

 

MP NP

 

 

5

1

5

 

 

 

I.M. injection 150 micrograms in 0.3 mL single dose syringe auto‑injector (EpiPen Jr.)

Injection

 

EpiPen Jr.

AL

MP NP

C4909 C4946 C4947

 

1

0

1

 

 

 

I.M. injection 300 micrograms in 0.3 mL single dose syringe auto‑injector (EpiPen)

Injection

 

EpiPen

AL

MP NP

C4909 C4946 C4947

 

1

0

1

 

 

Aflibercept

Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)

Injection

 

Eylea

BN

MP

C4154 C5453 C5521 C6599 C7078 C7100 C7101 C7132

P4154 P5521 P6599 P7100 P7101 P7132

1

2

1

 

 

 

 

 

 

 

 

MP

C4154 C5453 C5521 C6599 C7078 C7100 C7101 C7132

P5453 P7078

1

5

1

 

 

Albendazole

Tablet 200 mg

Oral

 

Zentel

AS

MP NP

C5680 C5712 C5797 C5817

P5712 P5797 P5817

6

0

6

 

 

 

 

 

 

 

 

MP NP

C5680 C5712 C5797 C5817

P5680

6

1

6

 

 

 

Tablet 400 mg

Oral

 

Eskazole

AS

MP

C5607

 

60

2

60

 

 

Alectinib

Capsule 150 mg

Oral

 

Alecensa

RO

MP

C7345 C7346 C7353

 

224

1

224

 

 

Alemtuzumab

Solution concentrate for I.V. infusion 12 mg in 1.2 mL

Injection

 

Lemtrada

GZ

MP

C6847 C6877 C6878 C6884

P6847 P6878

3

0

1

 

D(100)

 

 

 

 

 

 

MP

C6847 C6877 C6878 C6884

P6877 P6884

5

0

1

 

D(100)

Alendronic Acid

Tablet 70 mg (as alendronate sodium)

Oral

 

Alendrobell 70mg

GQ

MP NP

C6310 C6323 C6327

 

4

5

4

 

 

 

 

 

 

Alendronate Sandoz

SZ

MP NP

C6310 C6323 C6327

 

4

5

4

 

 

 

 

 

 

Alendro Once Weekly

RW

MP NP

C6310 C6323 C6327

 

4

5

4

 

 

 

 

 

 

APO‑Alendronate

TX

MP NP

C6310 C6323 C6327

 

4

5

4

 

 

 

 

 

 

Densate 70

DO

MP NP

C6310 C6323 C6327

 

4

5

4

 

 

 

 

 

 

Fonat

AL

MP NP

C6310 C6323 C6327

 

4

5

4

 

 

Alendronic acid with colecalciferol

Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol

Oral

a

Alendronate plus D3-DRLA

RZ

MP NP

C6307 C6315 C6320

 

4

5

4

 

 

 

 

 

a

Alendronate Plus D3 Sandoz

SZ

MP NP

C6307 C6315  C6320

 

4

5

4

 

 

 

 

 

a

APO-Alendronate Plus D3 70 mg/70 mcg

TX

MP NP

C6307 C6315  C6320

 

4

5

4

 

 

 

 

 

a

Chem mart Alendronate Plus D3 70 mg/70 mcg

CH

MP NP

C6307 C6315  C6320

 

4

5

4

 

 

 

 

 

a

FonatPlus

AF

MP NP

C6307 C6315  C6320

 

4

5

4

 

 

 

 

 

a

Fosamax Plus

MK

MP NP

C6307 C6315  C6320

 

4

5

4

 

 

 

 

 

a

Terry White Chemists Alendronate Plus D3 70 mg/70 mcg

TW

MP NP

C6307 C6315  C6320

 

4

5

4

 

 

 

Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol

Oral

a

Alendronate plus D3-DRLA

RZ

MP NP

C6306 C6319 C6325

 

4

5

4

 

 

 

 

 

a

Alendronate Plus D3 Sandoz

SZ

MP NP

C6306 C6319 C6325

 

4

5

4

 

 

 

 

 

a

APO-Alendronate Plus D3 70 mg/140 mcg

TX

MP NP

C6306 C6319 C6325

 

4

5

4

 

 

 

 

 

a

Chem mart Alendronate Plus D3 70 mg/140 mcg

CH

MP NP

C6306 C6319 C6325

 

4

5

4

 

 

 

 

 

a

Dronalen Plus

AL

MP NP

C6306 C6319 C6325

 

4

5

4

 

 

 

 

 

a

FonatPlus

AF

MP NP

C6306 C6319 C6325

 

4

5

4

 

 

 

 

 

a

Fosamax Plus 70 mg/140 mcg

MK

MP NP

C6306 C6319 C6325

 

4

5

4

 

 

 

 

 

a

Terry White Chemists Alendronate Plus D3 70 mg/140 mcg

TW

MP NP

C6306 C6319 C6325

 

4

5

4

 

 

Alendronic acid with colecalciferol and calcium

Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate)

Oral

 

Dronalen Plus D‑Cal

AL

MP NP

C6306 C6319 C6325

 

1

5

1

 

 

 

 

 

 

Fosamax Plus D‑Cal

MK

MP NP

C6306 C6319 C6325

 

1

5

1

 

 

 

 

 

 

ReddyMax Plus D-Cal

RZ

MP NP

C6306 C6319 C6325

 

1

5

1

 

 

Allopurinol

Tablet 100 mg

Oral

a

Allopurinol APOTEX

GX

MP NP

 

 

200

2

200

 

 

 

 

 

a

Allopurinol Sandoz

SZ

MP NP

 

 

200

2

200

 

 

 

 

 

a

Allosig

RF

MP NP

 

 

200

2

200

 

 

 

 

 

a

APO-Allopurinol

TX

MP NP

 

 

200

2

200

 

 

 

 

 

a

Chem mart Allopurinol

CH

MP NP

 

 

200

2

200

 

 

 

 

 

a

Progout 100

AF

MP NP

 

 

200

2

100

 

 

 

 

 

 

 

 

MP NP

 

 

200

2

200

 

 

 

 

 

a

Terry White Chemists Allopurinol

TW

MP NP

 

 

200

2

200

 

 

 

 

 

a

Zyloprim

RW

MP NP

 

 

200

2

200

 

 

 

Tablet 300 mg

Oral

a

Allopurinol APOTEX

GX

MP NP

 

 

60

2

60

 

 

 

 

 

a

Allopurinol Sandoz

SZ

MP NP

 

 

60

2

60

 

 

 

 

 

a

Allosig

RF

MP NP

 

 

60

2

60

 

 

 

 

 

a

APO-Allopurinol

TX

MP NP

 

 

60

2

60

 

 

 

 

 

a

Chem mart Allopurinol

CH

MP NP

 

 

60

2

60

 

 

 

 

 

a

Progout 300

AF

MP NP

 

 

60

2

60

 

 

 

 

 

a

Terry White Chemists Allopurinol

TW

MP NP

 

 

60

2

60

 

 

 

 

 

a

Zyloprim

RW

MP NP

 

 

60

2

60

 

 

Alogliptin

Tablet 6.25 mg (as benzoate)

Oral

 

Nesina

TK

MP NP

C4349

 

28

5

28

 

 

 

Tablet 12.5 mg (as benzoate)

Oral

 

Nesina

TK

MP NP

C4349

 

28

5

28

 

 

 

Tablet 25 mg (as benzoate)

Oral

 

Nesina

TK

MP NP

C4349

 

28

5

28

 

 

Alogliptin with metformin

Tablet containing 12.5 mg alogliptin (as benzoate) and 500 mg metformin hydrochloride

Oral

 

Nesina Met 12.5/500

TK

MP NP

C4423 C4427

 

56

5

56

 

 

 

Tablet containing 12.5 mg alogliptin (as benzoate) and 850 mg metformin hydrochloride

Oral

 

Nesina Met 12.5/850

TK

MP NP

C4423 C4427

 

56

5

56

 

 

 

Tablet containing 12.5 mg alogliptin (as benzoate) and 1 g metformin hydrochloride

Oral

 

Nesina Met 12.5/1000

TK

MP NP

C4423 C4427

 

56

5

56

 

 

Alprazolam

Tablet 250 micrograms

Oral

a

Kalma 0.25

AF

MP NP

C6773

 

10

0

10

 

 

 

 

 

 

 

 

MP NP

C6773

 

10

0

50

 

 

 

 

 

a

Alprax 0.25

QA

MP NP

C6773

 

10

0

50

 

 

 

Tablet 500 micrograms

Oral

a

Alprax 0.5

QA

MP NP

C6773

 

10

0

10

 

 

 

 

 

 

 

 

MP NP

C6773

 

10

0

50

 

 

 

 

 

a

Kalma 0.5

AF

MP NP

C6773

 

10

0

10

 

 

 

 

 

 

 

 

MP NP

C6773

 

10

0

50

 

 

 

Tablet 1 mg

Oral

a

Alprax 1

QA

MP NP

C6773

 

10

0

10

 

 

 

 

 

 

 

 

MP NP

C6773

 

10

0

50

 

 

 

 

 

a

Kalma 1

AF

MP NP

C6773

 

10

0

10

 

 

 

 

 

 

 

 

MP NP

C6773

 

10

0

50

 

 

Amantadine

Capsule containing amantadine hydrochloride 100 mg

Oral

 

Symmetrel 100

NV

MP NP

C5132

 

100

5

100

 

 

Ambrisentan

Tablet 5 mg

Oral

 

Volibris

GK

MP

See Note 3

See Note 3

See Note 3

See
Note 3

30

 

D(100)

 

Tablet 10 mg

Oral

 

Volibris

GK

MP

See Note 3

See Note 3

See Note 3

See
Note 3

30

 

D(100)

Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine

Sachets containing oral powder 20 g, 30 (PKU Go)

Oral

 

PKU Go

OH

MP NP

C4295

 

4

5

1

 

 

Amino acid formula with fat, carbohydrate, vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine and supplemented with docosahexanoic acid

Oral liquid 500 mL, 20 (PKU Baby)

Oral

 

PKU Baby

OH

MP NP

C4295

 

2

5

1

 

 

Amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexanoic acid

Oral liquid 125 mL, 36 (HCU Anamix junior LQ)

Oral

 

HCU Anamix junior LQ

SB

MP NP

C5534

 

4

5

1

 

 

Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine

Bottles containing oral powder 34 g, 30 (PKU Easy Shake & Go)

Oral

 

PKU Easy Shake & Go

OH

MP NP

C5970

 

5

5

1

 

 

Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine

Bottles containing oral powder 34 g, 30 (TYR Easy Shake & Go)

Oral

 

TYR Easy Shake & Go

OH

MP NP

C5533

 

4

5

1

 

 

Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexanoic acid

Oral liquid 125 mL, 36 (TYR Anamix junior LQ)

Oral

 

TYR Anamix junior LQ

SB

MP NP

C5533

 

4

5

1

 

 

Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides

Oral powder 400 g (Alfamino Junior)

Oral

 

Alfamino Junior

NT

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 C5945 C5974

 

8

5

1

 

 

 

Oral powder 400 g (Neocate Junior)

Oral

 

Neocate Junior

SB

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 C5945 C5974

 

8

5

1

 

 

Amino acid formula with fat, carbohydrate, without phenylalanine

Tablets (modified release), 70.8 g protein per 100 g, 110 g, 4 (PKU Easy Microtabs)

Oral

 

PKU Easy Microtabs

OH

MP NP

C5970

 

7

5

1

 

 

Amino acid formula without phenylalanine

Capsules 500 mg, 200 (Phlexy‑10)

Oral

 

Phlexy‑10

SB

MP NP

C4295

 

16

5

1

 

 

 

Tablets 1 g, 75 (Phlexy‑10)

Oral

 

Phlexy‑10

SB

MP NP

C4295

 

24

5

1

 

 

 

Sachets containing oral powder 20 g, 30 (Phlexy‑10 Drink Mix)

Oral

 

Phlexy‑10 Drink Mix

SB

MP NP

C4295

 

7

5

1

 

 

Amino acid formula without valine, leucine and isoleucine

Sachets containing oral powder 6 g, 30 (MSUD amino5)

Oral

 

MSUD amino5

VF

MP NP

C5571

 

12

5

1

 

 

Amino acid formula with vitamins and minerals, low phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid

Sachets containing oral powder 12.5 g, 30 (PKU Anamix First Spoon)

Oral

 

PKU Anamix First Spoon

SB

MP NP

C4295

 

8

5

1

 

 

Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine

Oral powder 400 g (PKU Anamix infant)

Oral

 

PKU Anamix infant

SB

MP NP

C4295

 

8

5

1

 

 

Amino acid formula with vitamins and minerals without lysine and low in tryptophan

Sachets containing oral powder 18 g, 30 (GA1 Anamix Junior)

Oral

 

GA1 Anamix Junior

NU

MP NP

C6007

 

8

5

1

 

 

 

Sachets containing oral powder 24 g, 30 (GA gel)

Oral

 

GA gel

VF

MP NP

C5323

 

4

5

1

 

 

 

Oral powder 400 g (GA1 Anamix infant)

Oral

 

GA1 Anamix infant

SB

MP NP

C5323

 

8

5

1

 

 

 

Oral powder 500 g (XLYS, LOW TRY Maxamum)

Oral

 

XLYS, LOW TRY Maxamum

SB

MP NP

C5323

 

9

5

1

 

 

 

Sachets containing oral powder 25 g, 30 (GA express 15)

Oral

 

GA express 15

VF

MP NP

C5323

 

4

5

1

 

 

Amino acid formula with vitamins and minerals without methionine

Oral powder 400 g (HCU Anamix infant)

Oral

 

HCU Anamix infant

SB

MP NP

C5559

 

8

5

1

 

 

 

Sachets containing oral powder 24 g, 30 (HCU gel)

Oral

 

HCU gel

VF

MP NP

C5534

 

4

5

1

 

 

 

Sachets containing oral powder 25 g, 30 (HCU express 15)

Oral

 

HCU express 15

VF

MP NP

C5534

 

4

5

1

 

 

 

Sachets containing oral powder 36 g, 30 (HCU Anamix Junior)

Oral

 

HCU Anamix Junior

NU

MP NP

C6038

 

4

5

1

 

 

 

Oral powder 500 g (XMET Maxamum)

Oral

 

XMET Maxamum

SB

MP NP

C5534

 

8

5

1

 

 

 

Oral liquid 87 mL, 30 (HCU cooler 10)

Oral

 

HCU cooler 10

VF

MP NP

C5534

 

4

5

1

 

 

 

Oral liquid 125 mL, 30 (HCU Lophlex LQ 20)

Oral

 

HCU Lophlex LQ 20

SB

MP NP

C5534

 

3

5

1

 

 

 

Oral liquid 130 mL, 30 (HCU cooler 15)

Oral

 

HCU cooler 15

VF

MP NP

C5534

 

4

5

1

 

 

 

Oral liquid 174 mL, 30 (HCU cooler 20)

Oral

 

HCU cooler 20

VF

MP NP

C5534

 

4

5

1

 

 

Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine

Sachets containing oral powder 18 g, 30 (MMA/PA Anamix Junior)

Oral

 

MMA/PA Anamix Junior

NU

MP NP

C5986 C6055

 

8

5

1

 

 

 

Sachets containing oral powder 25 g, 30 (MMA/PA express 15)

Oral

 

MMA/PA express 15

VF

MP NP

C5542 C5560

 

4

5

1

 

 

 

Sachets containing oral powder 24 g, 30 (MMA/PA gel)

Oral

 

MMA/PA gel

VF

MP NP

C5542 C5560

 

4

5

1

 

 

 

Oral powder 400 g (MMA/PA Anamix infant)

Oral

 

MMA/PA Anamix infant

SB

MP NP

C5542 C5560

 

8

5

1

 

 

 

Oral powder 500 g (XMTVI Maxamum)

Oral

 

XMTVI Maxamum

SB

MP NP

C5542 C5560

 

8

5

1

 

 

 

Oral liquid 130 mL, 30 (MMA/PA cooler 15)

Oral

 

MMA/PA cooler 15

VF

MP NP

C5542 C5560

 

4

5

1

 

 

Amino acid formula with vitamins and minerals without phenylalanine

Sachets containing oral powder 24 g, 30 (PKU gel)

Oral

 

PKU gel

VF

MP NP

C4295

 

4

5

1

 

 

 

Sachets containing oral powder 25 g, 30 (PKU express 15)

Oral

 

PKU express 15

VF

MP NP

C4295

 

4

5

1

 

 

 

Sachets containing oral powder 27.8 g, 30 (PKU Lophlex)

Oral

 

PKU Lophlex

SB

MP NP

C4295

 

4

5

1

 

 

 

Sachets containing oral powder 34 g, 30 (PKU express 20)

Oral

 

PKU express 20

VF

MP NP

C4295

 

4

5

1

 

 

 

Sachets containing oral powder 36 g, 30 (PKU Anamix Junior)

Oral

 

PKU Anamix Junior

SB

MP NP

C4964

 

4

5

1

 

 

 

Sachets containing oral powder 50 g, 30 (XP Maxamum)

Oral

 

XP Maxamum

SB

MP NP

C4295

 

3

5

1

 

 

 

Oral gel 85 g, 30 (PKU squeezie)

Oral

 

PKU squeezie

VF

MP NP

C4295

 

4

5

1

 

 

 

Oral powder 500 g (XP Maxamaid)

Oral

 

XP Maxamaid

SB

MP NP

C4295

 

8

5

1

 

 

 

Oral powder 500 g (XP Maxamum)

Oral

 

XP Maxamum

SB

MP NP

C4295

 

8

5

1

 

 

 

Oral liquid 250 mL (Easiphen)

Oral

 

Easiphen

SB

MP NP

C4295

 

90

5

18

 

 

 

Oral liquid 62.5 mL, 60 (PKU Lophlex LQ 10)

Oral

 

PKU Lophlex LQ 10

SB

MP NP

C4295

 

2

5

1

 

 

 

Oral liquid 87 mL, 30 (PKU Cooler 10)

Oral

 

PKU Cooler 10

VF

MP NP

C4295

 

4

5

1

 

 

 

Oral liquid 125 mL, 30 (PKU Lophlex LQ 20)

Oral

 

PKU Lophlex LQ 20

SB

MP NP

C4295

 

4

5

1

 

 

 

Oral liquid 125 mL, 36 (PKU Anamix Junior LQ)

Oral

 

PKU Anamix Junior LQ

SB

MP NP

C4295

 

4

5

1

 

 

 

Oral liquid 130 mL, 30 (PKU Air 15)

Oral

 

PKU Air 15

VF

MP NP

C4295

 

4

5

1

 

 

 

Oral liquid 130 mL, 30 (PKU Cooler 15)

Oral

 

PKU Cooler 15

VF

MP NP

C4295

 

4

5

1

 

 

 

Oral liquid 174 mL, 30 (PKU Air 20)

Oral

 

PKU Air 20

VF

MP NP

C4295

 

4

5

1

 

 

 

Oral liquid 174 mL, 30 (PKU Cooler 20)

Oral

 

PKU Cooler 20

VF

MP NP

C4295

 

4

5

1

 

 

 

Oral semi-solid 109 g, 36 (PKU Lophlex Sensation 20)

Oral

 

PKU Lophlex Sensation 20

SB

MP NP

C4295

 

3

5

1

 

 

Amino acid formula with vitamins and minerals without phenylalanine and tyrosine

Sachets containing oral powder 24 g, 30 (TYR gel)

Oral

 

TYR gel

VF

MP NP

C5533

 

4

5

1

 

 

 

Sachets containing oral powder 25 g, 30 (TYR express 15)

Oral

 

TYR express 15

VF

MP NP

C5533

 

4

5

1

 

 

 

Sachets containing oral powder 34 g, 30 (TYR express 20)

Oral

 

TYR express 20

VF

MP NP

C5533

 

4

5

1

 

 

 

Sachets containing oral powder 36 g, 30 (TYR Anamix Junior)

Oral

 

TYR Anamix Junior

SB

MP NP

C4923

 

4

5

1

 

 

 

Oral powder 400 g (TYR Anamix infant)

Oral

 

TYR Anamix infant

SB

MP NP

C5533

 

8

5

1

 

 

 

Oral powder 500 g (XPhen, Tyr Maxamum)

Oral

 

XPhen, Tyr Maxamum

SB

MP NP

C5533

 

8

5

1

 

 

 

Oral liquid 87 mL, 30 (TYR cooler 10)

Oral

 

TYR cooler 10

VF

MP NP

C5533

 

4

5

1

 

 

 

Oral liquid 125 mL, 30 (TYR Lophlex LQ 20)

Oral

 

TYR Lophlex LQ 20

SB

MP NP

C5533

 

3

5

1

 

 

 

Oral liquid 130 mL, 30 (TYR cooler 15)

Oral

 

TYR cooler 15

VF

MP NP

C5533

 

4

5

1

 

 

 

Oral liquid 174 mL, 30 (TYR cooler 20)

Oral

 

TYR cooler 20

VF

MP NP

C5533

 

4

5

1

 

 

Amino acid formula with vitamins and minerals without valine, leucine and isoleucine

Sachets containing oral powder 24 g, 30 (MSUD gel)

Oral

 

MSUD gel

VF

MP NP

C5571

 

4

5

1

 

 

 

Sachets containing oral powder 25 g, 30 (MSUD express 15)

Oral

 

MSUD express 15

VF

MP NP

C5571

 

4

5

1

 

 

 

Sachets containing oral powder 34 g, 30 (MSUD express 20)

Oral

 

MSUD express 20

VF

MP NP

C5571

 

4

5

1

 

 

 

Sachets containing oral powder 36 g, 30 (MSUD Anamix Junior)

Oral

 

MSUD Anamix Junior

SB

MP NP

C4954

 

4

5

1

 

 

 

Oral powder 400 g (MSUD Anamix infant)

Oral

 

MSUD Anamix infant

SB

MP NP

C5571

 

8

5

1

 

 

 

Oral powder 500 g (MSUD AID III)

Oral

 

MSUD AID III

SB

MP NP

C5571

 

4

5

1

 

 

 

Oral powder 500 g (MSUD Maxamum)

Oral

 

MSUD Maxamum

SB

MP NP

C5571

 

8

5

1

 

 

 

Oral liquid 87 mL, 30 (MSUD cooler 10)

Oral

 

MSUD cooler 10

VF

MP NP

C5571

 

4

5

1

 

 

 

Oral liquid 125 mL, 30 (MSUD Lophlex LQ 20)

Oral

 

MSUD Lophlex LQ 20

SB

MP NP

C5571

 

3

5

1

 

 

 

Oral liquid 130 mL, 30 (MSUD cooler 15)

Oral

 

MSUD cooler 15

VF

MP NP

C5571

 

4

5

1

 

 

 

Oral liquid 174 mL, 30 (MSUD cooler 20)

Oral

 

MSUD cooler 20

VF

MP NP

C5571

 

4

5

1

 

 

Amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexanoic acid

Oral liquid 125 mL, 36 (MSUD Anamix Junior LQ)

Oral

 

MSUD Anamix Junior LQ

SB

MP NP

C5571

 

4

5

1

 

 

Amino acids—synthetic, formula

Oral powder 400 g (EleCare)

Oral

 

EleCare

AB

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415

8

5

1

 

 

 

 

 

 

 

 

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4368 P4414

12

5

1

 

 

 

Oral powder 400 g (Neocate Advance)

Oral

 

Neocate Advance

SB

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415

 

8

5

1

 

 

 

Oral powder 400 g (Neocate Advance Vanilla)

Oral

 

Neocate Advance Vanilla

SB

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415

8

5

1

 

 

 

 

 

 

 

 

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4368 P4414

12

5

1

 

 

Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids

Oral powder 400 g (EleCare LCP)

Oral

 

EleCare LCP

AB

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415

 

8

5

1

 

 

 

Oral powder 400 g (Neocate LCP)

Oral

 

Neocate LCP

SB

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415

 

8

5

1

 

 

Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides

Oral powder 400 g (Alfamino)

Oral

 

Alfamino

NT

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415  C5945 C5974

 

8

5

1

 

 

 

Oral powder 400 g (Neocate Gold)

Oral

 

Neocate Gold

SB

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415

8

5

1

 

 

 

 

 

 

 

 

 

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4368 P4414

12

5

1

 

 

Amiodarone

Tablet containing amiodarone hydrochloride 100 mg

Oral

 

Aratac 100

AF

MP NP

C5665

 

30

5

30

 

 

 

 

 

 

Cordarone X 100

SW

MP NP

C5665

 

30

5

30

 

 

 

Tablet containing amiodarone hydrochloride 200 mg

Oral

a

Amiodarone Sandoz

SZ

MP NP

C5665

 

30

5

30

 

 

 

 

 

a

APO-Amiodarone

TX

MP NP

C5665

 

30

5

30

 

 

 

 

 

a

Aratac 200

AF

MP NP

C5665

 

30

5

30

 

 

 

 

 

a

Cordarone X 200

SW

MP NP

C5665

 

30

5

30

 

 

 

 

 

a

GenRx Amiodarone

GX

MP NP

C5665

 

30

5

30

 

 

 

 

 

a

Rithmik 200

RW

MP NP

C5665

 

30

5

30

 

 

Amisulpride

Tablet 100 mg

Oral

a

Amisulpride 100 Winthrop

WA

MP NP

C4246

 

30

5

30

 

 

 

 

 

a

Amisulpride AN

EA

MP NP

C4246

 

30

5

30

 

 

 

 

 

a

Amisulpride Sandoz

SZ

MP NP

C4246

 

30

5

30

 

 

 

 

 

a

APO‑Amisulpride

TX

MP NP

C4246

 

30

5

30

 

 

 

 

 

a

Pharmacor Amisulpride

CR

MP NP

C4246

 

30

5

30

 

 

 

 

 

a

Solian 100

SW

MP NP

C4246

 

30

5

30

 

 

 

 

 

a

Sulprix

AF

MP NP

C4246

 

30

5

30

 

 

 

Tablet 200 mg

Oral

a

Amisulpride 200 Winthrop

WA

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Amisulpride AN

EA

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Amisulpride Sandoz

SZ

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

APO‑Amisulpride

TX

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Pharmacor Amisulpride

CR

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Solian 200

SW

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Sulprix

AF

MP NP

C4246

 

60

5

60

 

 

 

Tablet 400 mg

Oral

a

Amipride 400

RW

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Amisulpride 400 Winthrop

WA

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Amisulpride AN

EA

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Amisulpride Sandoz

SZ

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

APO‑Amisulpride

TX

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Pharmacor Amisulpride

CR

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Solian 400

SW

MP NP

C4246

 

60

5

60

 

 

 

 

 

a

Sulprix

AF

MP NP

C4246

 

60

5

60

 

 

 

Oral solution 100 mg per mL, 60 mL

Oral

 

Solian Solution

SW

MP NP

C4246

 

2

5

1

 

 

Amitriptyline

Tablet containing amitriptyline hydrochloride 10 mg

Oral

a

Amitriptyline Alphapharm 10

AL

MP NP

 

 

50

2